Monday, January 25, 2010
Note: the use of surgical site checklists stemmed from WHO's Patient Safety group/s.
"For many cancer survivors, the fear of recurrence is oppressive. It hinders them from enjoying everyday activities and profoundly affects their quality of life. However, by learning to manage their anxieties, patients can become more confident about their survivorship."
"Women can explore clinical trials by visiting the Ovarian Cancer National Alliance Clinical Trials Matching Service online or by calling (800) 535-1682."
press release: Women's College Hospital (Toronto) offers Jewish women genetic screening for breast cancer
“Our study identified two major concerns with current breast cancer screening guidelines,” says Dr. Kelly Metcalfe, adjunct scientist at the Women’s College Research Institute and associate professor at the University of Toronto. “The first is that over half of the women we identified with a mutation would never have known that they were at an increased risk of cancer because they were not eligible for genetic testing outside of this study. The second concern was that although 45 per cent of the women with mutations were eligible for genetic testing based on their family history of cancer, none were referred by their health-care provider for screening. "
NCCN updates their guidelines annually - the guidelines on a variety of subjects (cancers/genetics etc) can be found at: http://www.nccn.org
Access requires registration but is free. There is a specific area for the genetics of breast/ovarian but to find genetics relating to Lynch Syndrome you need to go to the colorectal cancer section.
A Study Comparing Oral Picoplatin With Intravenous Picoplatin in Subjects With Solid Tumors - Full Text View - ClinicalTrials.gov
A Study Comparing Oral Picoplatin With Intravenous Picoplatin in Subjects With Solid Tumors - Full Text View - ClinicalTrials.gov:
"This study has been completed.
First Received: April 23, 2007 Last Updated: September 23, 2009
Sponsor: Poniard Pharmaceuticals
Information provided by: Poniard Pharmaceuticals
ClinicalTrials.gov Identifier: NCT00465725"
Pharma press release: re Phase 2 Trial of Picoplatin in Metastatic Colorectal Cancer Meets Primary Endpoint and Study Objectives
"Our ultimate goal is to secure a strategic partnership to support further development of picoplatin in CRC and other solid tumor indications, including prostate and ovarian cancers.'"
"In theory, Dooley said the technique could be used on any organ that could be "held relatively still." Scientists are now working to integrate heat-sensitive nanotechnology that would more precisely target cancer cells. They also plan to study a byproduct of the rapid disintegration of the tumor – a boosted immune system."